Phase 3, Randomized, Double Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 In Patients With Active Psoriatic Arthritis

Trial Profile

Phase 3, Randomized, Double Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 In Patients With Active Psoriatic Arthritis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2011

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Aug 2011 Planned number of patients changed to 600.
    • 09 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top